Patients have been asking about the new #COVID19 #antivirals.
I looked into the effectiveness of two well-publicised 'game changer' anti-virals, #Paxlovid and #Lagrevio
I looked into the effectiveness of two well-publicised 'game changer' anti-virals, #Paxlovid and #Lagrevio
On the Pfizer medication which has widespread coverage in the media - #Paxlovid - well it is unpublished, though the FDA issued an emergency approval. Pfizer website has minimal info.
But is looks like- for HIGH RISK patients only- it reduces the risk
But is looks like- for HIGH RISK patients only- it reduces the risk
of hospitalisation or death by 3.5% (that is 29 people needed to be treated, so that 1 benefits).
Caveats ++ as unsure on side effects, cost etc. but that is genuinely useful, yet prob not the 'gamechanger' for community care, which #COVIDcelebs would lead us believe.
Caveats ++ as unsure on side effects, cost etc. but that is genuinely useful, yet prob not the 'gamechanger' for community care, which #COVIDcelebs would lead us believe.
#Lagevrio was initially trialled on unvaccinated adults who were HIGH RISK (so the NEJM trial is out of date) but it also reduces risk of hospitalisation or death by 3.5%.
Will be interesting to see if there is any benefit for 'standard risk' populations.
Will be interesting to see if there is any benefit for 'standard risk' populations.
Suffice to say I hope we really wait for evidence before authorisation is provided in standard risk populations.
And we must remember that we should demand high-quality evidence and full access to data- otherwise things like this happen: bmj.com/content/348/bm…
And we must remember that we should demand high-quality evidence and full access to data- otherwise things like this happen: bmj.com/content/348/bm…
* The Paxlovid trial for high risk patients- I had typo above- relative risk is below. Thanks @RogerGalligan for pointing out +.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
